Mast Cells in Adjacent Normal Colon Mucosa Rather Than Those in Invasive Margin Are Related to Progression of Colon Cancer

Overview

Journal Chin J Cancer Res

Specialty Oncology

Date 2013 Jan 30

PMID 23358806

Citations 6

Authors

Qing Xia

Ya Ding

Xiao-Jun Wu

Rui-Qing Peng

Qiang Zhou

Jing Zeng

Jing-Hui Hou

Xing Zhang

Yi-Xin Zeng

Xiao-Shi Zhang

Ying-Bo Chen

Affiliations

Soon will be listed here.

Abstract

Objective: Mast cells (MC) reside in the mucosa of the digestive tract as the first line against bacteria and toxins. Clinical evidence has implied that the infiltration of mast cells in colorectal cancers is related to malignant phenotypes and a poor prognosis. This study compared the role of mast cells in adjacent normal colon mucosa and in the invasive margin during the progression of colon cancer.

Methods: Specimens were obtained from 39 patients with colon adenomas and 155 patients with colon cancers treated at the Sun Yat-sen University Cancer Center between January 1999 and July 2004. The density of mast cells was scored by an immunohistochemical assay. The pattern of mast cell distribution and its relationship with clinicopathologic parameters and 5-year survival were analyzed.

Results: The majority of mast cells were located in the adjacent normal colon mucosa, followed by the invasive margin and least in the cancer stroma. Mast cell count in adjacent normal colon mucosa (MCC(adjacent)) was associated with pathologic classification, distant metastases and hepatic metastases, although it was not a prognostic factor. In contrast, mast cell count in the invasive margin (MCC(invasive)) was associated with neither the clinicopathlogic parameters nor overall survival.

Conclusion: Mast cells in the adjacent normal colon mucosa were related to the progression of colon cancer, suggesting that mast cells might modulate tumor progression via a long-distance mechanism.

Citing Articles

Mast cells in colorectal cancer tumour progression, angiogenesis, and lymphangiogenesis.

Liu X, Li X, Wei H, Liu Y, Li N Front Immunol. 2023; 14:1209056.

PMID: 37497234 PMC: 10366593. DOI: 10.3389/fimmu.2023.1209056.

Immunological and prognostic significance of tumour necrosis in colorectal cancer.

Kastinen M, Sirnio P, Elomaa H, Ahtiainen M, Vayrynen S, Herzig K Br J Cancer. 2023; 128(12):2218-2226.

PMID: 37031328 PMC: 10241859. DOI: 10.1038/s41416-023-02258-2.

Comparative Study of the Role of Interepithelial Mucosal Mast Cells in the Context of Intestinal Adenoma-Carcinoma Progression.

Groll T, Silva M, Sarker R, Tschurtschenthaler M, Schnalzger T, Mogler C Cancers (Basel). 2022; 14(9).

PMID: 35565377 PMC: 9105816. DOI: 10.3390/cancers14092248.

The Regulation of Intestinal Inflammation and Cancer Development by Type 2 Immune Responses.

Gamez-Belmonte R, Erkert L, Wirtz S, Becker C Int J Mol Sci. 2020; 21(24).

PMID: 33371444 PMC: 7767427. DOI: 10.3390/ijms21249772.

High infiltration of mast cells positive to tryptase predicts worse outcome following resection of colorectal liver metastases.

Suzuki S, Ichikawa Y, Nakagawa K, Kumamoto T, Mori R, Matsuyama R BMC Cancer. 2015; 15:840.

PMID: 26530140 PMC: 4632336. DOI: 10.1186/s12885-015-1863-z.

References

Acikalin M, Oner U, Topcu I, Yasar B, Kiper H, Colak E . Tumour angiogenesis and mast cell density in the prognostic assessment of colorectal carcinomas. Dig Liver Dis. 2005; 37(3):162-9. DOI: 10.1016/j.dld.2004.09.028. View

Taweevisit M . The association of stromal mast cell response and tumor cell differentiation in colorectal cancer. J Med Assoc Thai. 2007; 89 Suppl 3:S69-73. View

Kalesnikoff J, Galli S . New developments in mast cell biology. Nat Immunol. 2008; 9(11):1215-23. PMC: 2856637. DOI: 10.1038/ni.f.216. View

Lachter J, Stein M, Lichtig C, Eidelman S, Munichor M . Mast cells in colorectal neoplasias and premalignant disorders. Dis Colon Rectum. 1995; 38(3):290-3. DOI: 10.1007/BF02055605. View

Carlini M, Dalurzo M, Lastiri J, Smith D, Vasallo B, Puricelli L . Mast cell phenotypes and microvessels in non-small cell lung cancer and its prognostic significance. Hum Pathol. 2009; 41(5):697-705. DOI: 10.1016/j.humpath.2009.04.029. View

Kashiwase Y, Inamura H, Morioka J, Igarashi Y, Kawai-Kowase K, Kurosawa M . Quantitative analysis of mast cells in benign and malignant colonic lesions: immunohistochemical study on formalin-fixed, paraffin-embedded tissues. Allergol Immunopathol (Madr). 2008; 36(5):271-6. DOI: 10.1016/s0301-0546(08)75222-4. View

Galli S, Grimbaldeston M, Tsai M . Immunomodulatory mast cells: negative, as well as positive, regulators of immunity. Nat Rev Immunol. 2008; 8(6):478-86. PMC: 2855166. DOI: 10.1038/nri2327. View

Peng S, Deng H, Yang J, Xie P, Li C, Li H . Significance and relationship between infiltrating inflammatory cell and tumor angiogenesis in hepatocellular carcinoma tissues. World J Gastroenterol. 2006; 11(41):6521-4. PMC: 4355797. DOI: 10.3748/wjg.v11.i41.6521. View

Fisher E, Paik S, Rockette H, Jones J, Caplan R, Fisher B . Prognostic significance of eosinophils and mast cells in rectal cancer: findings from the National Surgical Adjuvant Breast and Bowel Project (protocol R-01). Hum Pathol. 1989; 20(2):159-63. DOI: 10.1016/0046-8177(89)90180-9. View

10.

Gulubova M, Vlaykova T . Prognostic significance of mast cell number and microvascular density for the survival of patients with primary colorectal cancer. J Gastroenterol Hepatol. 2007; 24(7):1265-75. DOI: 10.1111/j.1440-1746.2007.05009.x. View

11.

Tan S, Fan Y, Luo H, Shen Z, Guo Y, Zhao L . Prognostic significance of cell infiltrations of immunosurveillance in colorectal cancer. World J Gastroenterol. 2005; 11(8):1210-4. PMC: 4250716. DOI: 10.3748/wjg.v11.i8.1210. View

12.

Galli S, Kalesnikoff J, Grimbaldeston M, Piliponsky A, Williams C, Tsai M . Mast cells as "tunable" effector and immunoregulatory cells: recent advances. Annu Rev Immunol. 2005; 23:749-86. DOI: 10.1146/annurev.immunol.21.120601.141025. View

13.

Wasiuk A, de Vries V, Hartmann K, Roers A, Noelle R . Mast cells as regulators of adaptive immunity to tumours. Clin Exp Immunol. 2008; 155(2):140-6. PMC: 2675243. DOI: 10.1111/j.1365-2249.2008.03840.x. View

14.

Groot Kormelink T, Abudukelimu A, Redegeld F . Mast cells as target in cancer therapy. Curr Pharm Des. 2009; 15(16):1868-78. DOI: 10.2174/138161209788453284. View

15.

Nechushtan H . The complexity of the complicity of mast cells in cancer. Int J Biochem Cell Biol. 2009; 42(5):551-4. DOI: 10.1016/j.biocel.2009.12.015. View

16.

Maltby S, Khazaie K, McNagny K . Mast cells in tumor growth: angiogenesis, tissue remodelling and immune-modulation. Biochim Biophys Acta. 2009; 1796(1):19-26. PMC: 2731828. DOI: 10.1016/j.bbcan.2009.02.001. View

17.

Metz M, Grimbaldeston M, Nakae S, Piliponsky A, Tsai M, Galli S . Mast cells in the promotion and limitation of chronic inflammation. Immunol Rev. 2007; 217:304-28. DOI: 10.1111/j.1600-065X.2007.00520.x. View

18.

Galinsky D, Nechushtan H . Mast cells and cancer--no longer just basic science. Crit Rev Oncol Hematol. 2008; 68(2):115-30. DOI: 10.1016/j.critrevonc.2008.06.001. View

19.

Nielsen H, Hansen U, Christensen I, Reimert C, Brunner N, Moesgaard F . Independent prognostic value of eosinophil and mast cell infiltration in colorectal cancer tissue. J Pathol. 2000; 189(4):487-95. DOI: 10.1002/(SICI)1096-9896(199912)189:4<487::AID-PATH484>3.0.CO;2-I. View

20.

Guidolin D, Nico B, Crivellato E, Marzullo A, Vacca A, Ribatti D . Tumoral mast cells exhibit a common spatial distribution. Cancer Lett. 2008; 273(1):80-5. DOI: 10.1016/j.canlet.2008.07.032. View